Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Vitamin C May Encourage Blood Cancer Stem Cells to Die

Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online August 17, 2017, in the journal Cell.

Read More »

Novo Nordisk’s semaglutide beats out Trulicity

Positive results were announced from Novo Nordisk’s SUSTAIN 7 Phase III trial comparing once-weekly semaglutide against Lilly’s Trulicity for type 2 diabetes.

Read More »

House Democrats launch MS drug pricing probe

House Committee on Oversight and Government Reform Democrats are launching an investigation into why prices for MS treatments have nearly quadrupled since 2004.

Read More »

Innovation and robotics will speed up tumor analysis

Genome BC is investing in a cancer research project that aims to speed up genetic tests of tumors through the development of a robotics system.

Read More »

Mylan, U.S. finalize EpiPen settlement

Mylan NV finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment.

Read More »

Arcus Biosciences, Wuxi Biologics Hammer Out R&D Cancer Pact Worth $816 Million+

One year after emerging from stealth mode, immuno-oncology startup Arcus Biosciences struck an exclusive licensing deal with Shanghai, China-based Wuxi Biologics for its anti-PD-1 antibody GLS-010.

Read More »

Johnson & Johnson CEO Backpedals and Quits Right Before Trump Disbands Council

One day after committing to remain on the President’s Manufacturing Council, Johnson & Johnson Chief Executive Officer Alex Gorsky reversed course and resigned from the council, shortly before the council as a whole was disbanded by President Donald Trump.

Read More »

Repatha Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine

Amgen announced that the New England Journal of Medicine published results from the Repatha (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).

Read More »

Trump to make August cost-sharing payments to health insurers

The Trump administration will make cost-sharing payments to insurance companies under Obamacare for August 2017, a White House spokesman said, but the announcement did little to quell long-term concerns about the insurance market.

Read More »

FDA Accepts Adcetris Supplemental BLA for CTLC

The FDA accepted for filing Seattle Genetics’ supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom